Evidence map›Paper›PMID 40279549›Full record

ArticleJournal of medicinal chemistry2025

Toward Dual-Target Glycomimetics against Two Bacterial Lectins to Fight

Giulia Antonini, Mario Fares, Dirk Hauck, Patrycja Mała, Emilie Gillon, Laura Belvisi, Anna Bernardi, Alexander Titz, Annabelle Varrot, Sarah Mazzotta

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Giulia AntoniniDipartimento di Chimica, Università degli Studi di Milano, Via Golgi 19, 20133 Milan, Italy.ORCID 0000-0002-4991-8731
Mario FaresHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research, D-66123 Saarbrücken, Germany.
Dirk HauckHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research, D-66123 Saarbrücken, Germany.
Patrycja MałaHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research, D-66123 Saarbrücken, Germany.
Emilie GillonCERMAV, Univ. Grenoble Alpes, CNRS, 38000 Grenoble, France.
Laura BelvisiDipartimento di Chimica, Università degli Studi di Milano, Via Golgi 19, 20133 Milan, Italy.ORCID 0000-0002-3593-2970
Anna BernardiDipartimento di Chimica, Università degli Studi di Milano, Via Golgi 19, 20133 Milan, Italy.ORCID 0000-0002-1258-2007
Alexander TitzHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research, D-66123 Saarbrücken, Germany.ORCID 0000-0001-7408-5084
Annabelle VarrotCERMAV, Univ. Grenoble Alpes, CNRS, 38000 Grenoble, France.ORCID 0000-0001-6667-8162
Sarah MazzottaDipartimento di Chimica, Università degli Studi di Milano, Via Golgi 19, 20133 Milan, Italy.ORCID 0000-0003-0029-7003

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic lung infections caused by

Indexed as

Anti-Bacterial AgentsBurkholderia cenocepaciaLectinsPseudomonas aeruginosaBurkholderia InfectionsHumansPseudomonas InfectionsStructure-Activity RelationshipAnti-Bacterial AgentsLecB protein, Pseudomonas aeruginosaLectins

Identifiers

PMID40279549
PMCPMC12067436

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.